TUB Financière de Tubize SA

252.92USD230.60 EUR · EBR-1.20%Mkt Cap: 11.26B USDP/E: 104.34

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous sys…

Institutional holders11 on file

Key Statistics

Company
Market Cap11.26B USD
Enterprise Value11.20B USD
Revenue (TTM)—
Gross Profit-3.25M USD
Net Income (TTM)102.25M USD
Revenue/Share—
Last Price252.92 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0003823409
Valuation
P/E (Trailing)104.34
P/E (Forward)—
PEG1.24
EV/EBITDA-3369.79
EV/Revenue—
P/S—
P/B5.17
EPS (TTM)2.42 USD
EPS (Forward)—
52W Range
184.3776% of range274.75
52W High274.75 USD
52W Low184.37 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE4.94%
ROA4.82%
ROIC-0.16%
ROCE-0.16%
Growth
Revenue Growth—
Earnings Growth5.40%
Cash Flow & Leverage
Operating CF-3.33M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-0.03%
Net Debt-54.73M USD
Net Debt/EBITDA16.46
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio141.92
Quick Ratio141.92
Book Value/Sh48.94 USD
Cash/Share1.23 USD
Dividends
Fwd Div Rate1.18 USD
Trail. Div Rate1.18 USD
Div. Yield0.46%
5Y Avg Yield0.76%
Payout Ratio48.85%
Ex-Div DateMay 7, 2026
Pay Date—
Splits
Last Split2:1
Split DateJun 17, 2005
Analyst Consensus
Rating—
Target (Mean)313.68 USD
Upside (mean)+24.0%
Target Range313.68 USD – 313.68 USD
# Analysts1
Ownership
Shares Out.44.51M
Float20.71M
Insiders53.49%
Institutions8.90%
Technical
SMA 50217.23 (+16.4%)
SMA 200227.89 (+11.0%)
Beta0.31
S&P 52W Chg12.00%
Avg Vol (30d)22.99K
Avg Vol (10d)17.36K
Technical Indicators
RSI (14)59.4
MACD11.2410
MACD Signal13.5075
MACD Hist.-2.2666
BB Upper274.68 USD
BB Middle255.57 USD
BB Lower236.45 USD
BB Width14.96%
ATR (14)6.642 USD
Vol Ratio (20d)0.45x

About Financière de Tubize (EBR: TUB)

›

Financière de Tubize (EBR: TUB) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 230.60 EUR on 19 November 2026, up 16.2% over 52 weeks. Its 52-week range is 168.10 EUR to 250.50 EUR: the price is 7.9% below the high and 37.2% above the low.

At a market capitalisation of 10.26B EUR, it trades at 104.3 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 211% for TUB. It pays a dividend yielding 0.46% (it pays out 49% of its earnings), against a median of 0.94% among the dividend payers in that peer group.

Financière de Tubize reports return on equity of 4.9% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 49.90M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 286.00 EUR is 24.0% above the current price. The next earnings report is expected on 20 March 2027.